Table 1 Changes over time in lead authorship, by topics, study design and region

TOTAL % (n)

58.4 (45)

60.8 (98)

60.1 (113.1)

0.74

 Haemorrhage

55.2 (4)

54.6 (7.5)

56.9 (8.8)

0.83

 Hypertension

90.3 (7)

76.7 (11.5)

86.0 (10.5)

0.86

 HIV

59.4 (15)

56.0 (35.3)

61.7 (42.8)

0.39

 STIs other than HIV

68.0 (4.3)

61.5 (6)

71.4 (4.3)

0.77

 Malaria

82.4 (7)

69.2 (13.5)

61.7 (15.8)

0.03

 Health Systems

42.1 (12)

52.9 (27)

52.8 (40.5)

0.09

 EmOC

35.7 (2.5)

42.1 (6)

46.4 (8.4)

0.32

 Demand-side Financing

75.0 (0.8)

58.3 (1.8)

51.2 (4.7)

0.35

 Equity examined

54.6 (3)

50.9 (7.3)

62.6 (14.3)

0.23

 TBA

13.3 (0.5)

65.2 (3.8)

42.2 (4.1)

0.25

 Effectiveness

60.0 (34.5)

63.8 (77.5)

60.2 (83.9)

0.72

 Randomised Controlled Trials

56.1 (9.3)

56.0 (14)

63.9 (16.3)

0.25

 Qualitative

66.7 (1)

56.1 (5.8)

58.2 (8.4)

0.92

 Mixed Methods

16.7 (0.3)

16.7 (0.8)

50.0 (4.5)

0.01

 Systematic Reviews^a

22.2 (1.5)

23.4 (3.8)

29.1 (9.4)

0.32

 Modelling Studies^a

33.3 (2.5)

21.6 (2.8)

35.4 (4.9)

0.57

 Multi-country study

42.1 (2)

43.5 (5)

41.0 (6.9)

0.86

 UMIC

81.8 (22.5)

78.5 (47.5)

80.5 (46.0)

0.94

 LMIC

48.2 (10)

53.2 (25.3)

59.0 (36.4)

0.06

 LIC

47.3 (13)

49.5 (26.5)

44.5 (32.3)

0.42

 East Asia Pacific

70.8 (8.5)

68.3 (10.8)

60.8 (12.6)

0.20

 Europe, Central Asia

66.7 (1.5)

83.3 (5)

63.0 (3.6)

0.45

 Latin America, Caribbean

70.2 (8.3)

70.6 (21)

76.4 (20.1)

0.31

 Middle East, North Africa

16.7 (0.25)

50.0 (2.3)

70.4 (4.1)

0.01

 South Asia

72.7 (6)

67.5 (13)

61.4 (17.3)

0.18

 Sub-Saharan Africa

52.9 (20.8)

54.2 (46.8)

55.4 (55.9)

0.56

 Papers in journal with IF

49.6 (28)

49.5 (57.3)

49.5 (65.1)

1.0

 Journal with IF 0–1.9

65.5 (9)

73.2 (20.5)

67.2 (27.6)

0.85

 Journal with IF 2–4.9

28.9 (3.8)

42.4 (13.3)

41.3 (18.2)

0.22

 Journal with IF ≥5

38.7 (3)

30.0 (4.5)

35.4 (6.2)

0.93